# Pilot Trial of Bavituximab Combined With Ribavirin for Initial Treatment of Chronic HepC Virus Genotype 1 Infection

> **NCT01273948** · PHASE1,PHASE2 · COMPLETED · sponsor: **Peregrine Pharmaceuticals** · enrollment: 66 (actual)

## Conditions studied

- Hepatitis C

## Interventions

- **DRUG:** Bavituximab
- **DRUG:** Pegylated interferon (PEG-IFN)

## Key facts

- **NCT ID:** NCT01273948
- **Lead sponsor:** Peregrine Pharmaceuticals
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2011-01
- **Primary completion:** 2012-01
- **Final completion:** 2012-02
- **Target enrollment:** 66 (ACTUAL)
- **Last updated:** 2012-02-06


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01273948

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01273948, "Pilot Trial of Bavituximab Combined With Ribavirin for Initial Treatment of Chronic HepC Virus Genotype 1 Infection". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT01273948. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*